Call for expressions of interest: Systematic reviews on hepatitis B and hepatitis C co-infection with TB and MDR/RR-TB and the effects of co-administration of MDR/RR-TB and hepatitis C treatment

The World Health Organization (WHO) Global TB Program has initiated a process to conduct systematic reviews for the collection and assessment of available evidence on the prevalence of viral hepatitis B and C among patients with TB and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and whether the concurrent treatment of drug-resistant TB and hepatitis C is safe and increases the likelihood of treatment success and reduces unfavourable treatment outcomes.

The WHO Global TB Program is seeking support from an independent consultants or group/s of experts with relevant expertise and experience to undertake systematic reviews to synthesise the evidence on the above-mentioned topic.

The deadline for submission of expressions of interest is 30 April 2021.

For further details, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By World Health Organization

Published: April 6, 2021, 3:35 p.m.

Last updated: April 13, 2021, 2:37 p.m.

Print Share